Three additional monoclonal antibodies directed against GM-CSF (gimsilumab, lenzilumab, and TJ003234) are currently under investigation for the treatment of COVID-19 (NCT04351243, NCT00995449, NCT03794180). This evidence concerns the gene CSF2 and COVID-19.